Journal of Veterinary Internal Medicine (Nov 2024)

Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study

  • Charles Hawkes,
  • Joanna Morris,
  • Spela Bavcar,
  • Craig Wilkie,
  • Surajit Ray,
  • Charlotte Auquier,
  • Sarah Benjamin,
  • Juan Borrego Massó,
  • Sébastien Bottin,
  • Owen Davies,
  • Isabelle Desmas‐Bazelle,
  • Anat Einhorn,
  • Celia Figueroa‐Gonzalez,
  • Katerina Holenova,
  • Elisavet Kritsotalaki,
  • Kerry Peak,
  • Katherine Smallwood,
  • Elisabetta Treggiari,
  • Paola Valenti,
  • Miguel Garcia de laVirgen,
  • Quentin Fournier

DOI
https://doi.org/10.1111/jvim.17222
Journal volume & issue
Vol. 38, no. 6
pp. 3193 – 3205

Abstract

Read online

Abstract Background Peripheral nodal B‐cell lymphomas (PNBCL) represent the most common presentation of lymphomas in dogs. Multiagent CHOP (C = cyclophosphamide, H = hydroxydaunorubicin [Doxorubicin], O = Oncovin, P = prednisolone)‐based chemotherapy protocols have been widely accepted as gold standard 1st‐line treatment. CHOP‐25 and CHOP‐19 are most commonly prescribed but have never been directly compared. Objectives Our primary aim was to compare outcomes of dogs diagnosed with PNBCL, treated using a 1st‐line CHOP‐19 or CHOP‐25 protocol. A secondary objective was to determine the impact of protocol‐related variables on outcomes. Animals Five hundred two dogs from 16 European oncology referral centers. One hundred fifty‐five dogs were treated with CHOP‐19 and 347 dogs with CHOP‐25. Methods Retrospective, multicentric cohort study of dogs diagnosed with PNBCL between 2014 and 2021. Results The 6‐month, 1‐year, and median progression‐free survival (PFS) were 56.5% (95% confidence interval [CI], 49.2‐65.0), 14.1% (95% CI, 9.4‐21.0), and 196 days (95% CI, 176‐233) with CHOP‐19; and 56.4% (95% CI, 51.4‐61.9), 17% (95% CI, 13.4‐21.6), and 209 days (95% CI, 187‐224) with CHOP‐25. The 1‐year, 2‐year and median overall survival (OS) were 36.9% (95% CI, 29.7‐46.0), 13.5% (95% CI, 8.6‐21.1), and 302 days (95% CI, 249‐338) with CHOP‐19; and 42.8% (95% CI, 37.7‐48.7), 15.4% (95% CI, 11.7‐20.4), and 321 days (95% CI, 293‐357) with CHOP‐25. No significant difference in PFS and OS was found between the 2 protocols. Conclusions and Clinical Importance Our study confirmed similar outcomes for dogs with PNBCL treated with 1st‐line CHOP‐19 or CHOP‐25. Both protocols therefore could be used as a standard of care in future trials.

Keywords